The 7th Annual Outsourcing in Clinical Trials DACH 2024 will take place on 29–30 October in Zurich, Switzerland. Credit: Arena International Events Group.

Europe has been a hotbed for pharmaceutical and medical device start-ups. Whilst the European biotech market trails behind the US, the area has seen several high-profile startups.

There has been a fall in venture capital (VC) financing in the pharmaceutical and medical device sector since 2022. As funding challenges remain for start-ups, the conference showcases a question-and-answer session on main investment criteria for VCs, hosted by Nadiia Wyttenbach, managing director of growth equity at Switzerland-based VC Redalpine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The upcoming 7th Annual Outsourcing in Clinical Trials DACH 2024 will take place on 29–30 October in Zurich, Switzerland.

The conference opens with a talk from Nicolas Le Bec, director of therapeutic area quality lead/global R&D quality at Bristol Myers Squibb. Le Bec explains the latest changes in European ICH GCP V3 regulatory requirements. The conference also boasts a session on pharmacovigilance in clinical trials in the DACH region (consisting of Germany, Austria and Switzerland) hosted by Joan D’souza, who is the contact person for pharmacovigilance for Swissmedic and BfArM, local regulatory authorities in Switzerland and Germany.

The first day also features sessions on incorporating emerging technologies like AI in clinical trials. A panel on revitalising clinical trials in the DACH region features experts from Novartis, Endotonics, ITM Isotopen Technologien München and T-CURX. The panellists will discuss the key challenges in conducting trials in the region and strategies to overcome these.

Diversity in clinical trials is one of the topics at the heart of the conference. Improving diversity in trials has been one of the key areas the industry has been working on over the past few years. Whilst multiple strides have been made in that direction, the experts in the pharmaceutical and medical device industry agree that barriers to diversifying clinical trials remain.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In September, the World Health Organization (WHO) released guidance on improving the design, conduct and oversight of clinical trials in countries of all income levels. The guidance aims to improve the inclusion of under-represented populations such as pregnant women and children in clinical trials. Vasee Moorthy, senior advisor of R&D at WHO, will discuss the new framework on the second day of the conference.

The conference is hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena.